Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
Terminated
Novartis Pharmaceuticals
Phase 2
The purpose of the study was to assess the effects of different doses of tropifexor (LJN452)
with respect to safety, tolerability, and on markers of liver inflammation in patients with
NASH
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
Completed
Allergan
Phase 2
The purpose of this study was to assess the safety, tolerability, and efficacy of a
combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with
nonalcoholic steatohepatitis (NASH) and liver fibrosis.
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
Completed
Novartis Pharmaceuticals
Phase 2
The purpose of this study was to assess the safety, tolerability, and efficacy of a
combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with
nonalcoholic steatohepatitis (NASH) and liver fibrosis.
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
Completed
Novartis Pharmaceuticals
Phase 1
The primary purpose of this study is to evaluate the effect of hepatic impairment on the
systemic exposure of tropifexor and to evaluate the safety of tropifexor in subjects with
hepatic impairment. The results of this study will support treatment and dosing decisions for
patients with varying degrees of hepatic impairment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
